Adverse events 2.0-Let us get SERIOs New reporting for adverse event outcomes needed in the era of immunooncology

Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, Mcarthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A (2019)

Publication Type: Journal article, Letter

Publication year: 2019

Journal

European Journal of Cancer Elsevier

Book Volume: 112

Pages Range: 29-31

DOI: 10.1016/j.ejca.2019.01.015

Authors with CRIS profile

Lucie Heinzerling Department of Dermatology

Involved external institutions

Fondazione IRCCS: Istituto Nazionale dei Tumori

Italy (IT) Universitätsspital Zürich (USZ)

Switzerland (CH) National and Kapodistrian University of Athens

Greece (GR) Aix-Marseille University / Aix-Marseille Université

France (FR) Université Sorbonne Paris Cité

France (FR) University of Sydney (USYD)

Australia (AU) Peter MacCallum Cancer Centre

Australia (AU) Vanderbilt University

United States (USA) (US) Massachusetts General Hospital

United States (USA) (US) University of California Los Angeles (UCLA)

United States (USA) (US) Institut Gustave-Roussy

France (FR) Universitätsklinikum Essen

Germany (DE) Memorial Sloan Kettering Cancer Center

United States (USA) (US) Universitätsklinikum Schleswig-Holstein (UKSH)

Germany (DE)

How to cite

APA:

Heinzerling, L., Ascierto, P.A., Dummer, R., Gogas, H., Grob, J.-J., Lebbe, C.,... Hauschild, A. (2019). Adverse events 2.0-Let us get SERIOs New reporting for adverse event outcomes needed in the era of immunooncology. European Journal of Cancer, 112, 29-31. https://dx.doi.org/10.1016/j.ejca.2019.01.015

MLA:

Heinzerling, Lucie, et al. "Adverse events 2.0-Let us get SERIOs New reporting for adverse event outcomes needed in the era of immunooncology." European Journal of Cancer 112 (2019): 29-31.

BibTeX: Download